[1]
|
Wiseman, M.J. (2019) Nutrition and Cancer: Prevention and Survival. British Journal of Nutrition, 122, 481-487.
https://doi.org/10.1017/S0007114518002222
|
[2]
|
Cao, M.M., et al. (2022) Current Cancer Burden in China: Epi-demiology, Etiology, and Prevention. Cancer Biology & Medicine, 19, 1121-1138. https://doi.org/10.20892/j.issn.2095-3941.2022.0231
|
[3]
|
Kitamura, T., Qian, B.Z. and Pollard, J.W. (2015) Im-mune Cell Promotion of Metastasis. Nature Reviews Immunology, 15, 73-86. https://doi.org/10.1038/nri3789
|
[4]
|
Wculek, S.K. and Malanchi, I. (2015) Neutrophils Support Lung Colonization of Metastasis-Initiating Breast Cancer Cells. Nature, 528, 413-417. https://doi.org/10.1038/nature16140
|
[5]
|
Hu, B., Yang, X.R., Xu, Y., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222.
https://doi.org/10.1158/1078-0432.CCR-14-0442
|
[6]
|
Chen, J.H., Zhai, E.T., Yuan, Y.J., et al. (2017) Systemic Immune-Inflammation Index for Predicting Prognosis of Colorectal Cancer. World Journal of Gastroenterology, 23, 6261-6272. https://doi.org/10.3748/wjg.v23.i34.6261
|
[7]
|
Qiu, Y., Zhang, Z. and Chen, Y. (2021) Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Gastric Cancer: A Meta-Analysis. Frontiers in Oncology, 11, Article ID: 537140.
https://doi.org/10.3389/fonc.2021.537140
|
[8]
|
Zhang, Y., Sun, Y. and Zhang, Q. (2020) Prognostic Value of the Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Meta-Analysis. Cancer Cell International, 20, Article No. 224.
https://doi.org/10.1186/s12935-020-01308-6
|
[9]
|
Li, J., Cao, D., Huang, Y., et al. (2022) The Prognostic and Clinicopathologf:ical Significance of Systemic Immune-Inflammation Index in Bladder Cancer. Frontiers in Immunology, 13, Article ID: 865643.
https://doi.org/10.3389/fimmu.2022.865643
|
[10]
|
Qi, W., Zhou, Y., Liu, Z., et al. (2022) Revealing the Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Patients with Different Stage Prostate Cancer: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 9, Article ID: 1052943. https://doi.org/10.3389/fmed.2022.1052943
|
[11]
|
Ohno, Y. (2019) Role of Systemic Inflammatory Response Markers in Urological Malignancy. International Journal of Urology, 26, 31-47. https://doi.org/10.1111/iju.13801
|
[12]
|
Güngör, N., Knaapen, A.M., Munnia, A., et al. (2010) Genotoxic Effects of Neutrophils and Hypochlorous Acid. Mutagenesis, 25, 149-154. https://doi.org/10.1093/mutage/gep053
|
[13]
|
Sandhu, J.K., Privora, H.F., Wenckebach, G., et al. (2000) Neutrophils, Nitric Oxide Synthase, and Mutations in the Mutatect Murine Tumor Model. The American Journal of Pathology, 156, 509-518.
https://doi.org/10.1016/S0002-9440(10)64755-4
|
[14]
|
Butin-Israeli, V., Bui, T.M., Wiesolek, H.L., et al. (2019) Neutrophil-Induced Genomic Instability Impedes Resolution of Inflammation and Wound Healing. Journal of Clinical Investigation, 129, 712-726.
https://doi.org/10.1172/JCI122085
|
[15]
|
Rodríguez-Berriguete, G., Sánchez-Espiridión, B., Cansino, J.R., et al. (2013) Clinical Significance of both Tumor and Stromal Expression of Components of the IL-1 and TNF-α Signaling Pathways in Prostate Cancer. Cytokine, 64, 555-563. https://doi.org/10.1016/j.cyto.2013.09.003
|
[16]
|
Deryugina, E.I., Zajac, E., Juncker-Jensen, A., et al. (2014) Tissue-Infiltrating Neutrophils Constitute the Major in Vivo Source of Angiogenesis-Inducing MMP-9 in the Tumor Microenvironment. Neoplasia, 16, 771-788.
https://doi.org/10.1016/j.neo.2014.08.013
|
[17]
|
Wang, Z., Yang, C., Li, L., et al. (2020) Tumor-Derived HMGB1 Induces CD62L(dim) Neutrophil Polarization and Promotes Lung Metastasis in Triple-Negative Breast Cancer. Onco-genesis, 9, Article No. 82.
https://doi.org/10.1038/s41389-020-00267-x
|
[18]
|
Morimoto-Kamata, R. and Yui, S. (2017) Insulin-Like Growth Factor-1 Signaling Is Responsible for Cathepsin G-Induced Aggregation of Breast Cancer MCF-7 Cells. Cancer Science, 108, 1574-1583.
https://doi.org/10.1111/cas.13286
|
[19]
|
Olsson, A.K. and Cedervall, J. (2018) The Pro-Inflammatory Role of Plate-lets in Cancer. Platelets, 29, 569-573.
https://doi.org/10.1080/09537104.2018.1453059
|
[20]
|
Liu, Y., Zhang, Y., Ding, Y., et al. (2021) Platelet-Mediated Tumor Metastasis Mechanism and the Role of Cell Adhesion Molecules. Critical Reviews in Oncology/Hematology, 167, Article ID: 103502.
https://doi.org/10.1016/j.critrevonc.2021.103502
|
[21]
|
Yan, M. and Jurasz, P. (2016) The Role of Platelets in the Tumor Microenvironment: From Solid Tumors to Leukemia. Biochimica et Biophysica Acta, 1863, 392-400. https://doi.org/10.1016/j.bbamcr.2015.07.008
|
[22]
|
Marra, P., Mathew, S., Grigoriadis, A., et al. (2014) IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers. Cancer Research, 74, 4908-4921.
https://doi.org/10.1158/0008-5472.CAN-14-0637
|
[23]
|
Mantovani, A., Allavena, P., Sica, A., et al. (2008) Can-cer-Related Inflammation. Nature, 454, 436-444.
https://doi.org/10.1038/nature07205
|
[24]
|
Gooden, M.J., de Bock G.H., Leffers, N., et al. (2011) The Prognostic Influence of Tumour-Infiltrating Lymphocytes in Cancer: A Systematic Review with Meta-Analysis. British Journal of Cancer, 105, 93-103.
https://doi.org/10.1038/bjc.2011.189
|
[25]
|
Ray-Coquard, I., Cropet, C., Van Glabbeke, M., et al. (2009) Lympho-penia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. Cancer Re-search, 69, 5383-5391.
https://doi.org/10.1158/0008-5472.CAN-08-3845
|
[26]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Can-cer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[27]
|
Peng, D., Gong, Y.Q., Hao, H., et al. (2017) Preoperative Prognostic Nu-tritional Index Is a Significant Predictor of Survival with Bladder Cancer after Radical Cystectomy: A Retrospective Study. BMC Cancer, 17, Article No. 391.
https://doi.org/10.1186/s12885-017-3372-8
|
[28]
|
Kang, M., Jeong, C.W., Kwak, C., et al. (2017) Preoperative Neutrophil-Lymphocyte Ratio Can Significantly Predict Mortality Outcomes in Patients with Non-Muscle Invasive Bladder Cancer Undergoing Transurethral Resection of Bladder Tumor. Oncotarget, 8, 12891-12901. https://doi.org/10.18632/oncotarget.14179
|
[29]
|
Kamoun, A., de Reyniès, A., Allory, Y., et al. (2020) A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. European Urology, 77, 420-433. https://doi.org/10.1016/j.eururo.2019.09.006
|
[30]
|
李攀, 王博文一, 洪星磊, 等. 术前系统免疫炎症指数对非肌层浸润性膀胱癌预后的评估价值[J]. 肿瘤基础与临床, 2022, 35(1): 23-27.
|
[31]
|
Gorgel, S.N., Akin, Y., Koc, E.M., et al. (2020) Retrospective Study of Systemic Immune-Inflammation Index in Muscle Invasive Bladder Cancer: In-itial Results of Single Centre. International Urology and Nephrology, 52, 469-473.
https://doi.org/10.1007/s11255-019-02325-9
|
[32]
|
Liu, P., Chen, S., Gao, X., et al. (2022) Preoperative Sarcopenia and Systemic Immune-Inflammation Index Can Predict Response to Intravesical Bacillus Calmette-Guerin Instillation in Patients with Non-Muscle Invasive Bladder Cancer. Frontiers in Immunology, 13, Article ID: 1032907. https://doi.org/10.3389/fimmu.2022.1032907
|
[33]
|
Zhou, Y., Zhang, Y., Li, W., et al. (2020) TCEAL2 as a Tumor Suppressor in Renal Cell Carcinoma Is Associated with the Good Prognosis of Patients. Cancer Management and Re-search, 12, 9589-9597.
https://doi.org/10.2147/CMAR.S271647
|
[34]
|
Hammers, H.J., Plimack, E.R., Infante, J.R., et al. (2017) Safety and Efficacy of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology, 35, 3851-3858. https://doi.org/10.1200/JCO.2016.72.1985
|
[35]
|
Ljungberg, B., Al-biges, L., Abu-Ghanem, Y., et al. (2019) European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European Urology, 75, 799-810. https://doi.org/10.1016/j.eururo.2019.02.011
|
[36]
|
Unverzagt, S., Moldenhauer, I., Nothacker, M., et al. (2017) Immunotherapy for Metastatic Renal Cell Carcinoma. Cochrane Database of Systematic Reviews, 5, D11673. https://doi.org/10.1002/14651858.CD011673.pub2
|
[37]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30.
https://doi.org/10.3322/caac.21590
|
[38]
|
Jin, M., Yuan, S., Yuan, Y., et al. (2021) Prognostic and Clinicopatholog-ical Significance of the Systemic Immune-Inflammation Index in Patients with Renal Cell Carcinoma: A Meta-Analysis. Frontiers in Oncology, 11, Article ID: 735803. https://doi.org/10.3389/fonc.2021.735803
|
[39]
|
Ozbek, E., Be-siroglu, H., Ozer, K., et al. (2020) Systemic Immune Inflammation Index Is a Promising Non-Invasive Marker for the Prognosis of the Patients with Localized Renal Cell Carcinoma. International Urology and Nephrology, 52, 1455-1463. https://doi.org/10.1007/s11255-020-02440-y
|
[40]
|
Teishima, J., Inoue, S., Hayashi, T., et al. (2020) Impact of the Systemic Immune-Inflammation Index for the Prediction of Prognosis and Modification of the Risk Model in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors. Canadian Urological Associa-tion Journal, 14, E582-E587.
https://doi.org/10.5489/cuaj.6413
|
[41]
|
Bedke, J., Albiges, L., Capitanio, U., et al. (2021) The 2021 Updated Euro-pean Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-Based Combination Therapies for Treatment-Naive Metastatic Clear-Cell Renal Cell Carcinoma Are Standard of Care. European Urology, 80, 393-397.
https://doi.org/10.1016/j.eururo.2021.04.042
|
[42]
|
Massari, F., Rizzo, A., Mollica, V., et al. (2021) Immune-Based Combinations for the Treatment of Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomised Clinical Trials. European Journal of Cancer, 154, 120-127.
https://doi.org/10.1016/j.ejca.2021.06.015
|
[43]
|
Stühler, V., Herrmann, L., Rausch, S., et al. (2022) Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipili-mumab plus Nivolumab. Cancers (Basel), 14, Article No. 2972. https://doi.org/10.3390/cancers14122972
|
[44]
|
蔡会龙, 原伟光, 刘思奇, 等. 1990年和2019年中国前列腺癌疾病负担及危险因素研究[J]. 临床泌尿外科杂志, 2022, 37(10): 749-752.
|
[45]
|
Dong, L., Su, Y., Zhu, Y., et al. (2022) The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy. Journal of Nuclear Medicine, 63, 248-252. https://doi.org/10.2967/jnumed.121.262411
|
[46]
|
Schwarzenboeck, S.M., Rauscher, I., Bluemel, C., et al. (2017) PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 58, 1545-1552. https://doi.org/10.2967/jnumed.117.191031
|
[47]
|
Rajwa, P., Schuettfort, V.M., D’Andrea, D., et al. (2021) Impact of Systemic Immune-Inflammation Index on Oncologic Outcomes in Patients Treated with Radical Prostatectomy for Clinically Nonmetastatic Prostate Cancer. Urologic Oncology, 39, 719-785. https://doi.org/10.1016/j.urolonc.2021.05.002
|
[48]
|
Wang, S., Yang, X., Yu, Z., et al. (2022) The Values of Sys-temic Immune-Inflammation Index and Neutrophil-Lymphocyte Ratio in Predicting Biochemical Recurrence in Patients with Localized Prostate Cancer after Radical Prostatectomy. Frontiers in Oncology, 12, Article ID: 907625. https://doi.org/10.3389/fonc.2022.907625
|
[49]
|
Zhang, B. and Xu, T. (2023) Prognostic Significance of Pretreat-ment Systemic Immune-Inflammation Index in Patients with Prostate Cancer: A Meta-Analysis. World Journal of Surgi-cal Oncology, 21, Article No. 2.
https://doi.org/10.1186/s12957-022-02878-7
|
[50]
|
Man, Y.N. and Chen, Y.F. (2019) Systemic Im-mune-Inflammation Index, Serum Albumin, and Fibrinogen Impact Prognosis in Castration-Resistant Prostate Cancer Patients Treated with First-Line Docetaxel. International Urology and Nephrology, 51, 2189-2199. https://doi.org/10.1007/s11255-019-02265-4
|
[51]
|
Neuberger, M., Skladny, J., Goly, N., et al. (2022) Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hor-mone-Sensitive Prostate Cancer Treated with Docetaxel Chemotherapy. AntiCancer Research, 42, 1911-1918. https://doi.org/10.21873/anticanres.15668
|